Open AccessP922: HEALTH‐RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B‐CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC‐1
Author(s) -
Popat R.,
Moreau P.,
Usmani S. Z.,
Garfall A.,
Mateos M.V.,
SanMiguel J. F.,
Oriol A.,
Nooka A. K.,
Rosinol L.,
Chari A.,
Karlin L.,
Krishnan A.,
Bahlis N.,
Martin T.,
Besemer B.,
MartínezLópez J.,
Delforge M.,
Fastenau J.,
Gries K. S.,
Donk N. W.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846556.04927.df
Subject(s) - medicine , multiple myeloma , quality of life (healthcare) , daratumumab , cohort , refractory (planetary science) , antibody , progressive disease , oncology , clinical trial , disease , immunology , bortezomib , astrobiology , physics , nursing